Mary Jones

A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours

Irene Braña, Raanan Berger, Talia Golan et al. · British Journal of Cancer · 2014 · 88 citations · Full text

A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML)

Farhad Ravandi, Ivana Gojo, Mrinal M. Patnaik et al. · Leukemia Research · 2016 · 53 citations · Full text

Hematological Malignancy, Oncology, Mixed-phenotype Acute Leukemia +8

A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer

Hope S. Rugo, Olivier Trédan, Jungsil Ro et al. · Breast Cancer Research and Treatment · 2017 · 34 citations · Full text

Advanced Breast Cancer, Breast Oncology, Medicine +7

Objective evaluation of bradykinesia in Parkinson’s disease using an inexpensive marker-less motion tracking system

Wee Lih Lee, Nicholas C. Sinclair, Mary Jones et al. · Physiological Measurement · 2019 · 25 citations

A palm-worn device to quantify rigidity in Parkinson’s disease

Thushara Perera, Wee-Lih Lee, Mary Jones et al. · Journal of Neuroscience Methods · 2019 · 20 citations

Kinesiology, Medicine, Parkinson Disease +10